
    
      Patients more than 11 years with body surface area more than 1.2m2, progressing after
      standard treatment, will be eligible to receive 250 or 500 mg of apatinib once daily together
      with SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until progression or unacceptable
      toxicity. The primary end point was progression-free survival (PFS) at 4 months and overall
      survival(OS). Secondary objectives were clinical benefit rate (CBR), defined as no
      progression at 6 months and safety.
    
  